FAZ Analysis

FAZ Analysis

The foveal avascular zone is the retina's most precise ischemia marker. It is the capillary-free circle at the center of the fovea — a deliberate anatomical feature that maximizes visual acuity by eliminating the optical distortion that vessels would introduce at the point of highest cone density. Its size and shape encode the cumulative history of foveal capillary loss.

Before OCTA, the FAZ could be imaged by fluorescein angiography — but FA required dye injection, referral, and was impractical as a serial monitoring tool. OCTA measures the FAZ objectively, automatically, at every macular scan, without any patient burden. This is one of the clearest examples of how OCTA changes what optometrists can monitor at the primary care level.

FAZ Metrics: Area, Perimeter, and Circularity

Modern OCTA platforms output three FAZ measurements automatically when a 3×3mm macular OCTA scan is acquired. Understanding what each measures and what it means clinically is the foundation for using FAZ data in patient management.

Area (mm²): The total area enclosed by the FAZ boundary, measured on the SCP slab. Normal range: 0.20–0.40mm² (normative values vary slightly by ethnicity and axial length). Area is the primary measurement for ischemia quantification. Values above 0.45mm² are considered pathologically enlarged in most published guidelines. Area increases as capillaries at the foveal perimeter are progressively lost — each increment represents irreversible loss of perifoveal capillary support.

Perimeter (mm): The total length of the FAZ boundary contour. In a perfectly circular FAZ, the perimeter is a simple function of area. As the FAZ margin becomes irregular — scalloped, asymmetric, or disrupted by focal NPA — the perimeter increases relative to area. An elevated perimeter-to-area ratio signals FAZ shape irregularity even when total area remains within normal limits.

Circularity Index: Calculated as 4π × Area / Perimeter². A perfect circle has a circularity index of 1.0. As the FAZ becomes more irregular, the index decreases toward 0. Values below 0.7 indicate clinically significant FAZ irregularity in most disease contexts. The circularity index is particularly valuable for detecting early FAZ disruption in patients where the total area is still within the normal range but the shape is already being distorted by focal capillary loss.

DCP FAZ: The FAZ is also measurable on the DCP slab, where it is typically 10–15% larger than the SCP FAZ. Some platforms report DCP FAZ separately. DCP FAZ enlargement may precede SCP FAZ enlargement in early diabetic retinopathy, consistent with the DCP's greater sensitivity to early capillary loss discussed in the previous module.

Measurement reproducibility: FAZ metrics are only meaningful as longitudinal monitoring tools if the acquisition conditions are consistent. For serial FAZ comparison to be valid: the same scan protocol (3×3mm), the same slab (SCP), and an adequate signal strength (≥7) are required at every visit. Platform-specific normal values differ slightly — always compare within the same platform when monitoring longitudinally.

FAZ Enlargement in Diabetic Retinopathy and RVO

The two most common causes of pathological FAZ enlargement in optometric practice are diabetic retinopathy and retinal vein occlusion. Understanding the mechanism and progression pattern for each allows you to use FAZ metrics purposefully in management.

Diabetic Retinopathy:

In DR, FAZ enlargement is the direct result of progressive perifoveal capillary non-perfusion. The process begins at the DCP with pericyte loss and microaneurysm formation, advancing to capillary closure. As the capillaries immediately surrounding the FAZ are lost, the avascular zone expands outward. The ETDRS study established that FAZ area correlates with visual function — a finding that predates OCTA but that OCTA now allows us to act on with objective quantification.

The DR staging progression on OCTA:

• Early NPDR: DCP perivenular dropout visible on 3×3mm. FAZ area in low-normal range but circularity may already show subtle reduction.
• Moderate NPDR: FAZ expansion begins on SCP slab. Area typically 0.35–0.50mm². NPA visible between the arcades on DCP. Circularity index declining.
• Severe NPDR: FAZ area often >0.50mm². Multiple large NPA zones. FAZ margins scalloped and irregular. Intraretinal microvascular abnormalities (IRMA) visible as irregular vessel loops at the NPA borders.
• PDR: FAZ area typically >0.80mm², often >1.0mm² with extensive ischemia. NVE/NVD appear on SCP slab. FAZ margins severely disrupted.

Practical use: In patients with moderate NPDR on clinical exam, a FAZ area >0.45mm² or circularity index <0.75 on OCTA is a signal that ischemic progression is occurring even if the clinical exam appears stable. This warrants shortened recall intervals and documented monitoring.

Retinal Vein Occlusion:

RVO causes acute ischemia from venous stasis. The FAZ response depends on the location of the occlusion:

• CRVO: All quadrants are affected. FAZ enlargement can be rapid and dramatic — area can reach 1.0mm² or more within weeks of the acute event. The degree of FAZ enlargement at presentation is a strong predictor of visual prognosis: patients with FAZ >1.0mm² at presentation rarely recover better than 20/100 even with successful anti-VEGF treatment of macular edema.
• BRVO: FAZ involvement depends on whether the occlusion affects the temporal arcades (which border the FAZ) or a more peripheral branch. Temporal BRVO with FAZ involvement has a significantly worse visual prognosis than superior or inferior BRVO where the FAZ is partially or fully spared.

An important prognostic principle: FAZ enlargement from ischemia is irreversible. Anti-VEGF treatment reduces macular edema and may improve VA when edema was the primary cause of reduced vision — but it cannot restore capillaries that are already lost. This is why FAZ measurement at baseline is critical for counseling patients with vein occlusion: edema can resolve; ischemic damage cannot.

FAZ Disruption Patterns

FAZ enlargement (size increase) and FAZ disruption (shape change) are related but distinct findings. Both occur in ischemic disease, but they can progress independently and carry different clinical implications.

Scalloped FAZ margins: The most common disruption pattern. Instead of a smooth curve, the FAZ boundary shows an irregular, scalloped edge — the result of focal capillary loss at specific points around the FAZ perimeter rather than uniform expansion. Each indentation represents a cluster of perifoveal capillaries that has been lost, leaving the FAZ boundary to track along the edge of viable capillaries. Scalloping is detectable by reduced circularity index (CI <0.7) even before total area exceeds the normal range. This makes the CI a sensitive early marker in patients with diabetic retinopathy where the total area is still borderline.

Eccentric FAZ: Normally, the foveal center (peak cone density, point of fixation) lies approximately at the geometric center of the FAZ. In eccentric FAZ patterns, the FAZ is asymmetric — one side has expanded much more than the opposite side, displacing the apparent center of the avascular zone relative to the anatomical fovea. This pattern indicates asymmetric capillary loss, often from branch-pattern NPA or from the edge effects of a BRVO in one quadrant. Clinically, eccentric FAZ is associated with eccentric fixation in advanced cases.

FAZ disruption without enlargement: In some early disease states, the FAZ shape becomes irregular (CI reduced, margins scalloped) while total area remains within normal limits. This pattern is clinically significant: it indicates ongoing capillary loss at the foveal perimeter that has not yet expanded the total zone but will if not monitored. The circularity index detects this earlier than area alone. This is why reporting both area and CI — not just area — adds clinical value.

FAZ in other conditions:

• Sickle cell retinopathy: FAZ enlargement is a primary OCTA finding, often preceding visible sea-fan NV or vitreous hemorrhage. FAZ monitoring by OCTA is becoming part of the standard retinal surveillance protocol for sickle cell patients.
• Radiation retinopathy: Post-radiation FAZ enlargement follows a similar pattern to DR — progressive NPA expansion.
• Macular telangiectasia type 2 (MacTel): FAZ disruption is a characteristic finding, but the mechanism is different — capillary remodeling and Müller cell loss rather than ischemic closure. The OCTA findings in MacTel are distinctive and recognizable once you have seen several cases.

FAZ in Clinical Practice: Integrating Metrics

FAZ metrics are only useful if they are integrated into a clinical workflow that records them, trends them, and acts on the trends. A single FAZ measurement tells you where the patient is today. Serial measurements tell you whether the disease is progressing, stabilizing, or responding to intervention.

Building a FAZ monitoring protocol:

1. Establish a baseline at diagnosis. For any patient with DR (any stage), RVO, sickle cell retinopathy, or other conditions that can cause FAZ enlargement — record FAZ area, perimeter, and CI at the first OCTA exam. Document the scan protocol (3×3mm), slab (SCP), and signal strength.
2. Consistent acquisition at every visit. Use the same protocol, same slab, same centration. Signal strength must be ≥7 for the metrics to be comparable. If a visit scan has SS <7, note it and do not compare metrics from that scan to previous values.
3. Define your action thresholds. A >10% increase in FAZ area between visits is clinically significant. CI dropping below 0.75 in a previously normal patient warrants a note. These thresholds should be recorded in the problem-oriented plan for each patient, not just observed and forgotten.
4. Use FAZ for prior authorization documentation. Anti-VEGF treatment for diabetic macular edema or RVO macular edema requires documentation of disease severity. Objective OCTA data — including FAZ area and NPA quantification — strengthens prior authorization submissions and documents medical necessity.

The Maestro2 workflow: The Maestro2 outputs FAZ area, perimeter, and circularity automatically on every 3×3mm macular OCTA acquisition. The report includes a color-coded overlay of the FAZ boundary superimposed on the SCP en face image, with trend data visible when prior scans are in the patient record. This automated output eliminates manual measurement variability and makes serial FAZ monitoring practical as part of every monitoring visit for at-risk patients.

Communicating FAZ findings to patients: Most patients do not understand FAZ metrics. What they understand is: "The area of blood vessels missing around the center of your vision has grown by 15% since your last visit. That means we need to watch this more closely — the missing vessels do not come back, but we can try to slow down the process." Translating the metric into a plain-language risk statement is part of the clinical utility of FAZ monitoring.